Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR001 plus standard chemotherapy in previously treated PDAC
CTR20254516Phase 2Active
- Sponsor
- Medcare
- Start
- Dec 2025
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MR001 in pancreatic adenocarcinoma (PDAC), sponsored by Medcare. Started Dec 2025; status: active.
02
Drugs
MR001
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20254516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254516.